Ewing’s Sarcoma of the Chest Wall (Askin Tumor)

Overview

Ewing’s sarcoma is a fast‑growing malignant tumor that originates in the bone or soft tissue. When it arises in the soft tissue of the chest wall, it is historically called an Askin tumor. This subtype was first described by Dr. Askin in 1979 and is classified within the Ewing sarcoma family of tumors (ESFT).

Key points:

• Population affected: Primarily children and adolescents, with a median age of 15 years; however, cases can occur in adults up to their 30s.
• Gender: Slight male predominance (≈ 55 % male).
• Prevalence: Ewing sarcoma accounts for ~1 % of all childhood cancers. Chest‑wall involvement is rare, representing 1–2 % of all Ewing sarcoma cases (American Cancer Society, 2023).

Symptoms

Symptoms often develop quickly over weeks to months. Because the tumor grows near vital structures (ribs, lungs, pleura), clinical presentation can be variable.

• Pain or tenderness over the chest wall – often described as a dull, persistent ache that worsens at night or with activity.
• Visible or palpable mass – a firm, sometimes firm‑to‑hard lump under the skin, which may enlarge rapidly.
• Swelling or skin changes – reddening, warmth, or ulceration over the tumor.
• Respiratory symptoms – shortness of breath, cough, or wheezing if the tumor presses on the lung or airway.
• Chest wall deformity – visible indentation or bulge, especially in growing children.
• Fever, night sweats, or weight loss – systemic signs that may suggest metastasis or tumor‑related inflammation.
• Pneumothorax – sudden collapse of a lung can occur if the tumor ruptures the pleura; presents with sharp chest pain and sudden shortness of breath.
• Neurologic symptoms – rare, but compression of nearby nerves can cause tingling or weakness in the arm.

Causes and Risk Factors

The exact cause of Ewing’s sarcoma is not fully understood, but research points to genetic alterations.

Genetic driver

• Most cases harbor a translocation t(11;22)(q24;q12) that creates the EWSR1‑FLI1 fusion gene, resulting in uncontrolled cell growth.
• Less common translocations involve EWSR1‑ERG or other partner genes.

Risk factors

• Age: Peak incidence between 10–20 years.
• Sex: Slightly higher in males.
• Race/ethnicity: Higher rates in Caucasians; lower in Asian and African populations (CDC, 2022).
• Family history: No strong hereditary pattern, but rare familial cases linked to germline EWSR1 alterations have been reported.
• Radiation exposure: Prior therapeutic radiation may increase risk, though most cases arise without known exposure.

Diagnosis

Because early signs mimic benign conditions (e.g., infections, rib fracture), a systematic approach is essential.

Clinical evaluation

• Detailed history (onset, growth rate, systemic symptoms).
• Physical examination focusing on size, consistency, mobility, and involvement of surrounding structures.

Imaging studies

• Chest X‑ray: First‑line; may reveal a soft‑tissue mass, rib destruction, or pleural effusion.
• Magnetic Resonance Imaging (MRI): Gold standard for local staging; delineates tumor extent, neurovascular involvement, and marrow infiltration.
• Computed Tomography (CT) scan: Helpful for assessing bone erosion and detecting lung metastases.
• Positron Emission Tomography (PET‑CT): Provides metabolic activity information and helps identify distant spread.

Biopsy

Definitive diagnosis requires tissue analysis.

• Core needle biopsy (image‑guided) is preferred for accuracy while preserving surgical planes.
• Open surgical biopsy may be necessary if needle biopsy is inconclusive.

Pathology & molecular testing

• Histology shows small round blue cells with scant cytoplasm.
• Immunohistochemistry: Positive for CD99 (MIC2) in >90 % of cases.
• Fluorescence in situ hybridization (FISH) or RT‑PCR confirms the characteristic EWSR1 translocation.

Staging

Based on the American Joint Committee on Cancer (AJCC) staging system, incorporating tumor size, local invasion, nodal involvement, and presence of metastases (commonly lung, bone, or bone marrow).

Treatment Options

Management requires a multidisciplinary team (pediatric oncology, orthopedic/ thoracic surgery, radiation oncology, radiology, pathology, and supportive care).

Neoadjuvant (pre‑surgical) therapy

• Multi‑agent chemotherapy – the backbone of treatment. Typical regimens (VAC/IE) include:
  • Vincristine
  • Actinomycin‑D (Dactinomycin)
  • Cyclophosphamide
  • Ifosfamide
  • Etoposide
  Duration: 6–9 cycles over 12–16 weeks. Chemotherapy shrinks the tumor, treats microscopic disease, and improves surgical outcomes (Mayo Clinic, 2023).
• Targeted agents (investational) – IGF‑1R inhibitors, PARP inhibitors, and newer TKIs are under clinical trials (NCT04084439). Use remains limited to trial settings.

Surgical resection

• Goal: Achieve wide negative margins (R0 resection) while preserving respiratory function.
• Procedures may involve removal of involved ribs, chest wall reconstruction with prosthetic mesh, muscle flaps, or‑custom 3‑D‑printed implants.
• In cases where complete excision is impossible, surgery is combined with high‑dose radiation.

Radiation therapy

• Indications: Positive margins, unresectable disease, or residual tumor after chemotherapy.
• Techniques: Intensity‑modulated radiation therapy (IMRT) or proton beam therapy to spare heart and lungs.
• Typical dose: 45–55 Gy in 1.8–2 Gy fractions.

Adjuvant (post‑operative) therapy

• Additional chemotherapy (often the same agents) for 6–12 months to eradicate micrometastatic disease.
• Radiation (if not given pre‑operatively) to the tumor bed.

Supportive & lifestyle measures

• Antiemetic medications (e.g., ondansetron) to control chemotherapy‑induced nausea.
• Growth‑factor support (filgrastim) to reduce neutropenia.
• Physical therapy to maintain chest wall mobility and lung capacity.
• Psychosocial counseling for patients and families.

Living with Ewing’s Sarcoma of the Chest Wall (Askin Tumor)

Because treatment is intensive and prolonged, ongoing self‑care is essential.

Follow‑up schedule

• Every 3 months for the first 2 years, then every 6 months up to 5 years, and annually thereafter.
• Each visit typically includes physical exam, chest imaging (X‑ray or MRI), and lab work (CBC, renal & liver panels).

Managing side effects

• Fatigue: Balance rest with light activity; consider short, frequent walks.
• Mucositis & nausea: Maintain good oral hygiene, use prescribed mouth rinses, and follow anti‑nausea regimens.
• Infertility: Discuss sperm banking (men) or egg preservation (women) before starting chemotherapy.
• Bone health: Calcium & vitamin D supplementation; weight‑bearing exercises as tolerated.

Psychosocial health

• Join support groups (e.g., St. Jude Children’s Research Hospital “Children’s Oncology Group”).
• School re‑integration programs help manage missed coursework.
• Mind‑body practices (yoga, guided imagery) can reduce anxiety.

Daily practical tips

• Keep a medication diary to avoid missed doses.
• Use a humidifier if radiation causes dry cough.
• Wear a protective mask in crowded places to reduce infection risk during periods of neutropenia.
• Maintain a balanced diet rich in protein to support healing.

Prevention

Because Askin tumors are driven by spontaneous genetic changes, there are no proven primary prevention strategies. However, general cancer‑preventive measures are advisable:

• Avoid unnecessary radiation exposure (e.g., limit repeated CT scans when alternative imaging suffices).
• Maintain a healthy lifestyle—nutrition, regular physical activity, and adequate sleep—to support immune surveillance.
• For families with a known hereditary cancer syndrome (rare), seek genetic counseling.

Complications

If left untreated or if treatment fails, serious complications can arise:

• Local invasion – destruction of ribs, collapse of the chest wall, leading to chronic pain and respiratory compromise.
• Pneumothorax or hemothorax – life‑threatening accumulation of air or blood in the pleural space.
• Metastatic spread – most commonly to lungs, other bones, and bone marrow; associated with a 5‑year survival of <10 % in metastatic disease (CDC, 2022).
• Treatment‑related toxicities – cardiotoxicity from anthracyclines, secondary leukemias from alkylating agents, and secondary solid tumors after radiation.
• Psychological impact – depression, anxiety, and post‑traumatic stress are common in adolescents facing aggressive cancer therapy.

When to Seek Emergency Care

---

**References** (selected)

1. Mayo Clinic. “Ewing sarcoma.” Updated 2023. https://www.mayoclinic.org
2. American Cancer Society. “Childhood cancers facts & figures.” 2023. https://www.cancer.org
3. CDC. “Bone and Soft‑Tissue Sarcoma in Children.” 2022. https://www.cdc.gov
4. NIH National Cancer Institute. “Ewing family of tumors Treatment (PDQ®)–Patient Version.” 2024. https://www.cancer.gov
5. Cleveland Clinic. “Askin tumor (Ewing sarcoma of the chest wall).” 2023. https://my.clevelandclinic.org
6. World Health Organization. “Classification of Tumours of Soft Tissue and Bone.” 2020.